

 IRIS AperTOUNIVERSITÀ  
DEGLI STUDI  
DI TORINO

This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in CYTOTHERAPY, 19 (5), 2017, 10.1016/j.jcyt.2017.02.329.

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

- (1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.
- (2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.
- (3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>), 10.1016/j.jcyt.2017.02.329

The publisher's version is available at:

<http://linkinghub.elsevier.com/retrieve/pii/S1465324917303870>

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/>

This full text was downloaded from iris - AperTO: <https://iris.unito.it/>

---

iris - AperTO

University of Turin's Institutional Research Information System and Open Access Institutional Repository

## **Human adipose stromal cells resist the detrimental effects of hyperglycaemic modified extracellular matrix in contrast to human retinal pericytes**

**H Kremer<sup>1</sup>, S Elvers-Hornung<sup>1</sup>, A Fiori<sup>1</sup>, E Beltramo<sup>2</sup>, M Harmsen<sup>3</sup>, H Hammes<sup>4</sup>, K Bieback<sup>1,5</sup>**

<sup>1</sup>*Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Europe, Germany*

<sup>2</sup>*Dept of Medical Sciences, University of Turin, Turin, Italy*

<sup>3</sup>*Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands*

<sup>4</sup>*5th Medical Department, University Medical Center, University of Heidelberg, Mannheim, Germany*

<sup>5</sup>*FlowCore Mannheim, Mannheim, Baden-Württemberg, Germany*

Diabetic retinopathy, the leading cause of blindness in the Western world, is characterized by an early loss of pericytes accompanied with thickening of the basement membrane and changes of the extracellular matrix (ECM) of connected endothelial cells. In models of diabetic retinopathy, adipose stromal cells acquired pericyte features and provided retinal microvascular support, suggesting functional replacement of pericytes. In contrast to pericytes, ASC appear to be refractory to hyperglycemic conditions. To address this, we first tested the effects of hyperglycemia on basic ASC features and second assessed whether high-glucose conditioned extracellular matrix affects adhesion and growth of ASC.

First, human ASC were isolated and expanded in normal (NG, 5.6 mmol/l) or high glucose (HG, 28 mmol/l) containing medium. Proliferation, differentiation and immunomodulatory capacities were compared. Second, human ASC and human retinal pericytes (HRP, primary and Bmi-1 immortalized) were seeded on ECM produced by human umbilical vein endothelial cells (HUVEC) under varying glucose conditions: NG, HG, or intermitted phases of hyperglycemia (every 3h during daytime). Adhesion and cell confluency on the ECM were monitored using kinetic live cell imaging. Apoptotic events were assessed using a fluorescent caspase 3 substrate.

ASC functional features were not affected by HG, supporting notions that ASC are refractory to hyperglycemia. Also, in contrast to HRP, they resisted the detrimental effects of constant hyperglycemic modified ECM of endothelial cells (ECM<sub>NG</sub> ASC and HRP =100%, ECM<sub>HG</sub> ASC=in average 110% and ECM<sub>HG</sub> HRP 85%,  $p \leq 0.05$ ). Only intermitted phases of hyperglycemia affected the adhesion and growth of ASC (95% versus ECM<sub>NG</sub> 12-16hours after seeding). The higher sensitivity of HRP to hyperglycemic-modified ECM was apparent by the occurrence of apoptotic events, rarely seen in ASC.

Our data document that ASC, in contrast to HRP, resist the detrimental effects of constant hyperglycemia. Thus they may serve as corrective against hyperglycemia-induced pericyte death or dysfunction reducing microvascular complications. Whether the angiogenic, secretory and immunomodulatory properties of ASC contribute further to prevent/treat diabetic complications is a matter of current studies.